Atopic Dermatitis (Eczema) can be uncomfortable, itchy, embarrassing and painful that affects millions of children and adults in the United States. While the exact causes of Atopic Dermatitis is unknown, the inflammation is attributed to the body's immune system overreaction to allergens, irritants, bacteria and other environmental factors.
Investigational treatment BRE-AD01 is a one time subcutaneous (under the skin) injection which utilizes exosome therapy in order to rejuvenate growth within the skin tissue and suppress inflammation while boosting the body's immune defense system in order to repair and protect the skin.
BRE-AD01 uses cutting edge research to produce a state-of-the-art exosome treatment to promote skin regeneration and suppress inflammation.
In various pre-clinical models, BRE-AD01 has demonstrated superior therapeutic effects compared to competing treatments such as JAK inhibitors (upadacitinib, baricitinib) and steroids while exhibiting no side-effects in tested animals.
BRE-AD01 also has has multiple Mechanisms of Actions (MOAs) that it utilizes such as repressing type 2 immune reaction, regulating IL-31R, and promoting skin barrier recovery.
If you are interested in participating in this study, please contact us below to talk with a study coordinator who can answer any of your questions while guiding you through each step of the process. Connect with us today and see if CartiLife is right for you.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of BxC-I17e Administered Subcutaneously in Patients with Moderate to Severe Atopic Dermatitis
Contact us today and see if you are eligible to enroll in a clinical trials.
A one-time subcutaneous (just below the skin) injection of treatment compound BxC-I17e.
8 Total Visits (1 Screening Visit, 1 Treatment Visit, 6 Follow-up Visits in the 6 months after Treatment)
* Sponsor: Brexogen, Inc.
* CRO: KCRN Research, Inc.
This BRE-AD01 Atopic Dermatitis treatment study is currently enrolling patients at these two locations in the United States.
3400 Civic Center Blvd
7th Floor, South Pavilion, Workstation #33
Philadelphia, PA 19104
4261 Stockton Drive
Suite 203
North Little Rock, AR 72117
207 House Avenue
Suite 102
Camp Hill, PA 17011
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.
To request more information about the study or to participate in our clinical trial,
please email us at info@epassrecruit.com or call us at 301-540-2600.
This CartiLife® study is being held at multiple location sites in United States.
ePASS Solutions, LLC.